Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216060 | 1.00 | KDM1A (0.38) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL31414602 | 0.81 | CA1 (0.40) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL19000144 | 0.81 | CA1 (0.40) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL2463116 | 0.80 | CA1 (0.32) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL16117797 | 0.80 | POLB (0.41) | KDM1AKCNH2KDM1BALOX5APFEN1 | |
| SCHEMBL31643021 | 0.80 | CA1 (0.32) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL29386666 | 0.79 | KDM1A (0.38) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL5691327 | 0.79 | CA1 (0.34) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL30486929 | 0.79 | CA1 (0.34) | KDM1AKCNH2KDM1BCA1CA2 | |
| SCHEMBL239637 | 0.79 | KDM1A (0.38) | KDM1AKCNH2KDM1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4620472-A2 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12421241-B2 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4617273-A1 | FUSED TRICYCLIC PARP1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4497438-B1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4355749-B1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| CN-102596937-A | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2012-07-18 | — | — | CN | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011006903-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | KDM1A 4145/4885KCNH2 1097/4885KDM1B 3639/4885 |
| US-12421241-B2 | Substituted pyridines as PARP1 inhibitors | PARP1, PARP11, PARP12 | KDM1A 356/4885KCNH2 4492/4885KDM1B 371/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | KDM1A 1004/4885KCNH2 2138/4885KDM1B 654/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | KDM1A 1079/4885KCNH2 758/4885KDM1B 336/4885 |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | KDM1A 932/4885KCNH2 4412/4885KDM1B 1488/4885 |
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | SCN1B, OXER1, NR3C2 | KDM1A 715/4885KCNH2 37/4885KDM1B 427/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | KDM1A 1023/4885KCNH2 3998/4885KDM1B 2090/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | KDM1A 861/4885KCNH2 384/4885KDM1B 493/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | KDM1A 1004/4885KCNH2 2138/4885KDM1B 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.